However, due to the heterogeneity of HER-2-positive breast cancers, the response to NACT varies, with the probability of achieving pCR ranging from 20 to 80%, and some patients still fail to achieve pCR [13]. The gene discussed is ERBB2; the disease is breast carcinoma.